التفاصيل البيبلوغرافية
| العنوان: |
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy |
| المؤلفون: |
Madonna, Gabriele, Masucci, Giuseppe V., Capone, Mariaelena, Mallardo, Domenico, Grimaldi, Antonio Maria, Simeone, Ester, Vanella, Vito, Festino, Lucia, Palla, Marco, Scarpato, Luigi, Tuffanelli, Marilena, D'angelo, Grazia, Villabona, Lisa, Krakowski, Isabelle, Eriksson, Hanna, Simao, Felipe, Lewensohn, Rolf, Ascierto, Paolo Antonio |
| المصدر: |
Cancers; Aug2021, Vol. 13 Issue 16, p4164, 1p |
| مصطلحات موضوعية: |
EOSINOPHILS, IMMUNE checkpoint inhibitors, MELANOMA, MACHINE learning, METASTASIS, RETROSPECTIVE studies, IPILIMUMAB, CANCER patients, NEUTROPHILS, LYMPHOCYTES, LACTATE dehydrogenase, DESCRIPTIVE statistics, ALGORITHMS, IMMUNOTHERAPY, THERAPEUTICS |
| مصطلحات جغرافية: |
ITALY |
| مستخلص: |
Simple Summary: Immune checkpoint inhibitors have improved the prognosis for patients with advanced melanoma. Despite the recent success of immunotherapy, many patients still do not benefit from these treatments, and their real-life application may yield different outcomes compared to the advantage presented in clinical trials. There is therefore a need to select patients who can really benefit from these treatments. We have focused our study on a real-life retrospective analysis of metastatic melanoma patients treated with immunotherapy at a single institution—the Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" of Napoli, Italy. With the help of AI and machine learning we validated an algorithm based on clinical variables of patients—namely, the Clinical Categorization Algorithm (CLICAL)—that defines five predictable cohorts of benefit to immunotherapy with 95% accuracy. It can be a useful tool for the stratification of metastatic melanoma patients who may or may not improve from immunotherapy treatment. The real-life application of immune checkpoint inhibitors (ICIs) may yield different outcomes compared to the benefit presented in clinical trials. For this reason, there is a need to define the group of patients that may benefit from treatment. We retrospectively investigated 578 metastatic melanoma patients treated with ICIs at the Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" of Napoli, Italy (INT-NA). To compare patients' clinical variables (i.e., age, lactate dehydrogenase (LDH), neutrophil–lymphocyte ratio (NLR), eosinophil, BRAF status, previous treatment) and their predictive and prognostic power in a comprehensive, non-hierarchical manner, a clinical categorization algorithm (CLICAL) was defined and validated by the application of a machine learning algorithm—survival random forest (SRF-CLICAL). The comprehensive analysis of the clinical parameters by log risk-based algorithms resulted in predictive signatures that could identify groups of patients with great benefit or not, regardless of the ICI received. From a real-life retrospective analysis of metastatic melanoma patients, we generated and validated an algorithm based on machine learning that could assist with the clinical decision of whether or not to apply ICI therapy by defining five signatures of predictability with 95% accuracy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder